Celgene to File NDA for Ozanimod as Multiple Sclerosis Therapy
If ozanimod captures a significant share in the evolving multiple sclerosis market, it may have a positive impact on Celgene stock.
Celgene (CELG) is currently exploring CC-122, a novel CELMoD agent, as a treatment option for diffuse large B-cell lymphoma.
According to unaudited financial results for Celgene (CELG) on January 9, 2017, Otezla sales for 2016 were about $1.0 billion. That’s a YoY rise of about 116.0%.
Celgene (CELG) is exploring investigational drugs such as sotatercept and CC-486 (oral azacitidine) to treat patients suffering with various myeloid diseases.
Data from Celgene’s Phase 2 open-label long-term extension trial have shown that 61.0% of MDS patients achieved transfusion independence with luspatercept.
Celgene (CELG) has a comprehensive strategy to target patient segments with unmet demands. It’s expected to continue to dominate the multiple myeloma space in 2017.
Celgene (CELG) is focusing on myeloid disorders such as myelodysplastic syndromes (or MDS) and acute myeloid leukemia (or AML) as potential future growth opportunities.
According to unaudited financial results published by Celgene (CELG) on January 9, 2017, Revlimid sales for 2016 are about $7.0 billion, a YoY rise of about 20.0%.
In 2017, Celgene (CELG) expects to earn revenues of $13.0 billion–$13.4 billion, which would be a YoY (year-over-year) growth of around 18.0%.
In October 2015, Walgreens announced its plans to acquire Rite Aid for an enterprise value of $17.2 billion, including acquired net debt of $9.3 billion.
Bloomberg reported that the FTC seems unimpressed by Walgreens’ proposal to sell 865 Rite Aid stores to Fred’s to obtain clearance to acquire Rite Aid.
On December 19, 2016, Novartis (NVS) announced an agreement with Conatus for developing new oral treatments for various diseases associated with the liver.
Sandoz contributes nearly 20% to Novartis’s (BVS) total revenues.
Analysts expect Alcon’s 4Q16 revenues to decline due to lower equipment sales in the Surgical franchise, as well as lower sales in contact lens products in the Vision Care franchise.
Analysts expect an ~1.1% decline in Novartis’s (NVS) 4Q16 revenues to ~$12.4 billion following the effects of the acquisition and divestiture of several products.
The overall contribution of the Innovative Medicines segment is ~67% of Novartis’s total revenues.
Novartis (NVS) is set to release its 4Q16 earnings on January 25, 2017. Analysts estimate its 4Q16 earnings per share to be $1.12.
Johnson & Johnson’s (JNJ) 4Q16 segment-wise performance is expected to be positive across all segments including pharmaceuticals, consumer, and medical devices segments.
JNJ stock has returned nearly 18.1% in the last 12 months, and analysts estimate the stock might rise 9% over the next 12 months.
Johnson & Johnson (JNJ) has restructured its business over the last few years and divested some low profitability products.